3.1.4.17	(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone	IC50: 0.0001 mM, PDE3A; IC50: 0.00028 mM, PDE3B	8657	
3.1.4.17	(2R,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol	IC50: 0.0043 mM, PDE2	24063	
3.1.4.17	(2S,3R)-3-(7-amino-3H-imidazo[4,5-b]pyridin-3-yl)nonan-2-ol	-	83466	
3.1.4.17	(2Z)-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one	IC50: 0.000006 mM, PDE3; IC50: 0.0012 mM, PDE2; IC50: 0.015 mM, PDE1	7669	
3.1.4.17	(6aS,9aR)-3-benzyl-2-(biphenyl-4-ylmethyl)-5-methyl-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one	comparison of inhibitory effect on several recombinant human PDE isoforms. Effective PDE1 inhibitor in cellular context	138232	
3.1.4.17	(Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate	time-dependent and irreversible inactivation of PDE3A	71569	
3.1.4.17	(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)-phenyl)propyl)-5-(4-(trifluoromethyl)-1H-imidazol-1-yl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide	-	230720	
3.1.4.17	(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)-phenyl)propyl)-6-methyl-5-(4-methyl-1H-1,2,3-triazol-1-yl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide	-	230721	
3.1.4.17	1-(2-chlorophenyl)-4-methyl-8-[(morpholin-4-yl)methyl][1,2,4]triazolo[4,3-a]quinoxaline	compound shows good combined potency, acceptable brain uptake and high selectivity for both PDE2 and PDE10 enzymes. In microdosing experiment in rats, the compound shows preferential distribution in brain areas	230467	
3.1.4.17	1-(2-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione	-	24659